Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2016-10-24
- Target Recruit Count
- 30
- Registration Number
- NCT02943252
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, Beijing, China
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02878057
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 25
- Registration Number
- NCT02874651
- Locations
- 🇨🇳
Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, Guangdong, China
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 35
- Registration Number
- NCT02867956
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2016-08-11
- Target Recruit Count
- 30
- Registration Number
- NCT02863367
Study of Apatinib and MASCT in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- The First People's Hospital of Lianyungang
- Target Recruit Count
- 60
- Registration Number
- NCT02844881
- Locations
- 🇨🇳
The First's People Hospital of Lianyungang, Lianyungang, Jiangsu, China
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 246
- Registration Number
- NCT02824458
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2016-05-23
- Target Recruit Count
- 20
- Registration Number
- NCT02780778
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-05-17
- Target Recruit Count
- 20
- Registration Number
- NCT02774200
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02768415
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.